Drug Discovery

Forma Therapeutics, University of Oxford partner to advance DUB inhibitors development

Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.

Amneal, Impax form Amneal Pharmaceuticals

Amneal Pharmaceuticals and Impax Laboratories have completed their business combination to form Amneal Pharmaceuticals.

InDex Pharmaceuticals develops oral formulation of Cobitolimod

InDex Pharmaceuticals Holding has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract.

Casma Therapeutics raises $58.5m in Series A funding

Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.

Janssen Biotech to buy BeneVir Biopharm in $1bn deal

Janssen Biotech has agreed to acquire US-based BeneVir Biopharm, a biopharmaceutical company focused on developing oncolytic immunotherapies for cancer, in a deal worth $1.04bn.

Vivus to acquire product rights to Pancreaze from Janssen for $135m

Vivus has agreed to acquire all product rights for Pancreaze (pancrelipase) Delayed-Release Capsules in the US and Canada held by Janssen Pharmaceuticals, subject to certain closing conditions, including Hart-Scott-Rodino review.

C4XD, e-Therapeutics to collaborate on Parkinson’s Disease treatment

C4X Discovery (C4XD) has entered into a joint research collaboration with e-Therapeutics (ETX) to identify novel mechanisms for the treatment of Parkinson’s Disease (PD).

NXDC announces acquisition by German biotech firm

NX Development (NXDC), a privately-held life sciences company, has announced a merger acquisition under which NXDC became a wholly-owned subsidiary of photonamic GmbH & Co. KG (PHN).

PhoreMost, NeoPhore secure Innovate UK funding for small-molecule cancer immunotherapy program

PhoreMost and NeoPhore are set to receiv £1m of funding to develop a novel small-molecule cancer immunotherapy program following award of a Biomedical Catalyst grant in a recent Innovate UK competition.